Preoperative levels of bilirubin or creatinine adjusted by age can predict their reversibility after implantation of left ventricular assist device

Circulation Journal

Volumn 77, Issue 1, 2013, Pages 96-104

  Imamura, Teruhiko ^a   Kinugawa, Koichiro ^a   Shiga, Taro ^a   Endo, Miyoko ^a   Kato, Naoko ^a   Inaba, Toshiro ^a   Maki, Hisataka ^a   Hatano, Masaru ^a   Yao, Atsushi ^a   Nishimura, Takashi ^a   Hirata, Yasunobu ^a   Kyo, Shunei ^a   Ono, Minoru ^a   Nagai, Ryozo ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Heart failure; Liver; Renal failure; Transplantation; Ventricular assist device

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BRAIN NATRIURETIC PEPTIDE; CREATININE;

ADULT; AGE; ARTICLE; ARTIFICIAL VENTILATION; CONTINUOUS HEMODIAFILTRATION; DISEASE SEVERITY; EXTRACORPOREAL OXYGENATION; FEMALE; HEART FAILURE; HUMAN; INTRAAORTIC BALLOON PUMP; KIDNEY FUNCTION; LEFT VENTRICULAR ASSIST DEVICE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; PREDICTION; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SURVIVAL; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL;

ADULT; BILIRUBIN; CREATININE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; KIDNEY; LIVER; LIVER FAILURE; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; RENAL INSUFFICIENCY;

EID: 84871703780     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0686     Document Type: Article

References (33)

1. van Deursen VM, Damman K, Hillege HL, van Beek AP, van Veldhuisen DJ, Voors AA. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail 2010; 16: 84-90.
2. Kinugawa K. How to treat stage D heart failure?: When to implant left ventricular assist devices in the era of continuous flow pumps? Circ J 2011; 75: 2038-2045.
3. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-210.
4. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-e235.
5. Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates: 2006. J Heart Lung Transplant 2006; 25: 1024-1042.
6. Chokshi A, Cheema FH, Schaefle KJ, Jiang J, Collado E, Shahzad K, et al. Hepatic dysfunction and survival after orthotopic heart transplantation: Application of the MELD scoring system for outcome prediction. J Heart Lung Transplant 2012; 31: 591-600.
7. Singh TP, Almond CS, Semigran MJ, Piercey G, Gauvreau K. Risk prediction for early in-hospital mortality following heart transplantation in the United States. Circ Heart Fail 2012; 5: 259-266.
8. Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report-- 2011. J Heart Lung Transplant 2011; 30: 1078-1094.
9. Singh M, Shullo M, Kormos RL, Lockard K, Zomak R, Simon MA, et al. Impact of renal function before mechanical circulatory support on posttransplant renal outcomes. Ann Thorac Surg 2011; 91: 1348-1354.
10. Khot UN, Mishra M, Yamani MH, Smedira NG, Paganini E, Yeager M, et al. Severe renal dysfunction complicating cardiogenic shock is not a contraindication to mechanical support as a bridge to cardiac transplantation. J Am Coll Cardiol 2003; 41: 381-385.
11. Kamdar F, Boyle A, Liao K, Colvin-Adams M, Joyce L, John R. Effects of centrifugal, axial, and pulsatile left ventricular assist device support on end-organ function in heart failure patients. J Heart Lung Transplant 2009; 28: 352-359.
12. Russell SD, Rogers JG, Milano CA, Dyke DB, Pagani FD, Aranda JM, et al. Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation 2009; 120: 2352-2357.
13. Sasaoka T, Kato TS, Komamura K, Takahashi A, Nakajima I, Oda N, et al. Improved long-term performance of pulsatile extracorporeal left ventricular assist device. J Cardiol 2010; 56: 220-228.
14. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. The Fourth INTERMACS Annual Report: 4,000 implants and counting. J Heart Lung Transplant 2012; 31: 117-126.
15. Kirklin JK, Naftel DC, Stevenson LW, Kormos RL, Pagani FD, Miller MA, et al. INTERMACS database for durable devices for circulatory support: First annual report. J Heart Lung Transplant 2008; 27: 1065-1072.
16. Shiga T, Kinugawa K, Hatano M, Yao A, Nishimura T, Endo M, et al. Age and preoperative total bilirubin level can stratify prognosis after extracorporeal pulsatile left ventricular assist device implantation. Circ J 2011; 75: 121-128.
17. Imamura T, Kinugawa K, Shiga T, Endo M, Kato N, Inaba T, et al. Novel risk scoring system with preoperative objective parameters gives a good prediction of 1-year mortality in patients with a left ventricular assist device. Circ J 2012; 76: 1895-1903.
18. Imamura T, Kinugawa K, Shiga T, Endo M, Inaba T, Maki H, et al. Early decision for a left ventricular assist device implantation is necessary for patients with modifier A. J Artif Organs 2012 April 18 [Epub ahead of print].
19. Sandner SE, Zimpfer D, Zrunek P, Dunkler D, Schima H, Rajek A, et al. Renal function after implantation of continuous versus pulsatile flow left ventricular assist devices. J Heart Lung Transplant 2008; 27: 469-473.
20. Letsou GV, Myers TJ, Gregoric ID, Delgado R, Shah N, Robertson K, et al. Continuous axial-flow left ventricular assist device (Jarvik 2000) maintains kidney and liver perfusion for up to 6 months. Ann Thorac Surg 2003; 76: 1167-1170.
21. Bank AJ, Mir SH, Nguyen DQ, Bolman RM 3rd, Shumway SJ, Miller LW, et al. Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation. Ann Thorac Surg 2000; 69: 1369-1374; discussion 1375.
22. Reinhartz O, Farrar DJ, Hershon JH, Avery GJ Jr, Haeusslein EA, Hill JD. Importance of preoperative liver function as a predictor of survival in patients supported with Thoratec ventricular assist devices as a bridge to transplantation. J Thorac Cardiovasc Surg 1998; 116: 633-640.
23. Evidence-based practice guideline for the treatment of CKD. Nihon Jinzo Gakkai Shi 2009; 51: 905-1066 (in Japanese).
24. Kavarana MN, Pessin-Minsley MS, Urtecho J, Catanese KA, Flannery M, Oz MC, et al. Right ventricular dysfunction and organ failure in left ventricular assist device recipients: A continuing problem. Ann Thorac Surg 2002; 73: 745-750.
25. Kormos RL, Teuteberg JJ, Pagani FD, Russell SD, John R, Miller LW, et al. Right ventricular failure in patients with the HeartMate II continuous- flow left ventricular assist device: Incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg 2010; 139: 1316-1324.
26. Schmitt R, Coca S, Kanbay M, Tinetti ME, Cantley LG, Parikh CR. Recovery of kidney function after acute kidney injury in the elderly: A systematic review and meta-analysis. Am J Kidney Dis 2008; 52: 262-271.
27. Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N. Fulminant hepatic failure: Summary of a workshop. Hepatology 1995; 21: 240-252.
28. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345: 1435-1443.
29. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361: 2241-2251.
30. Yoshioka D, Sakaguchi T, Saito S, Miyagawa S, Nishi H, Yoshikawa Y, et al. Predictor of early mortality for severe heart failure patients with left ventricular assist device implantation. Circ J 2012; 76: 1631-1638.
31. Slaughter MS, Pagani FD, Rogers JG, Miller LW, Sun B, Russell SD, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant 2010; 29(Suppl): S1-S39.
32. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle Heart Failure Model: Prediction of survival in heart failure. Circulation 2006; 113: 1424-1433.
33. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53: 582-588.